As células-tronco mesenquimais (MSCs) são células multipotentes que tem o potencial de se diferenciarem em várias linhagens celulares in vitro e in vivo. Estas são encontradas em nichos específicos em muitos órgãos e tecidos adultos, tais como medula óssea, tecido adiposo, músculo, dente, cordão umbilical, pele, cartilagem articular, sendo facilmente isoladas, expandidas e com alta capacidade proliferativa in vitro. Assim, estas características têm despertado grande interesse na sua utilização como uma potencial fonte de células para o reparo e regeneração tecidual de diversos órgãos e tecidos. Pouco se conhece sobre as moléculas que são secretadas pelas MSCs para a matriz extracelular (MEC) e que estão na interface célula-matriz e estão presentes em vias de transdução de sinais intracelulares. Desta forma, o objetivo deste trabalho foi avaliar o perfil de expressão gênica de enzimas que remodelam a MEC (metaloproteinases de matriz MMPs: 15 membros) e seus inibidores (inibidores teciduais das metaloproteinases de matriz TIMPs: 4 membros e RECK) e proteína da membrana plasmática (Caveolina-1) durante a diferenciação osteogenica in vitro a partir de células-tronco mesenquimais da polpa dentária humana (DPSCs). Para tanto, utilizamos polpas dentárias humanas provenientes de terceiros molares de indivíduos adultos (18-32 anos n=3) e as DPSCs isoladas foram imunofenotipadas por citometria de fluxo, avaliada a taxa de proliferação, induzidas as diferenciações osteogênica (1, 7, 14, 21 e 28 dias) e adipogênica (28 dias) e os transcritos avaliados por PCR em tempo real. Estas células foram positivas para o marcadores CD29, CD105, STRO-1, CD44, CD90 negativas os marcadores para CD31, CD45, CD34 e CD14 e são capazes de se diferenciarem em osteoblastos e adipócitos. Verificamos que as MMP-2, MMP-3, MMP-13, MMP-14, MMP-25, TIMP-3, TIMP-4 e Caveolina-1 foram diferencialmente expressas durante a diferenciação osteogênica, sendo reguladas positivamente apenas no período de 28 dias pós indução e a TIMP-1 regulada positivamente desde o primeiro dia de indução. A MMP-11 e MMP-16 não foram detectadas nas DPSCs e nem durante a diferenciação osteogênica. Desta forma, concluímos que MMPs encontradas bem como a Caveolina-1 e as TIMP-3 e TIMP-4 podem estar participando dos dos eventos de diferenciação óssea em DPSCs, a TIMP-1 pode estar participando de eventos biológicos relacionados as propriedades do estado indiferenciado das DPSCs e da diferenciação óssea e que as MMP-11 e MMP-16 não são expressas pelas DPSCs e também não estão envolvidas na diferenciação osteogênica. / Mesenchymal stem cells (MSCs) are multipotent cells that have the potential to differentiate into various cell lineages in vitro and in vivo. These are found in specific niches in many adult organs and tissues, such as bone marrow, adipose tissue, muscle, tooth, umbilical cord, skin, cartilage, being easily isolated, expanded and high proliferative capacity in vitro. Thereby, these features have attracted great interest in its use as a potential source of cells for tissue repair and regeneration of various organs and tissues. Little is known about the molecules secreted by MSCs into the extracellular matrix (ECM), present at cell-matrix interface and present on intracellular signal transduction. Thus, the aim of this study was to evaluate gene expression profile of ECM remodeling enzymes (matrix metalloproteinases MMPs: 15 members) and their inhibitors (tissue inhibitors of matrix metalloproteinases TIMPs: 4 members and RECK) and plasma membrane proteins (Caveolin-1) that participate in signaling pathways during osteogenic differentiation in vitro from human dental pulp stem cells (DPSCs). Normal human impacted third molars were collected from adults (18-32 years-old n=3) and DPSCs isolated were immunophenotyping by flow cytometry, evaluated the proliferation ratio, induced to osteogenic (1, 7, 14, 21 and 28-days) and adipogenic differentiation (28-days) and the transcript levels evaluated by Real Time PCR. These cells are positive for CD29, CD105, STRO -1, CD44, and CD90 markers and negative for CD31, CD45, CD34, and CD14 markers and are capable of differentiating into osteoblasts and adipocytes. We found that MMP- 2, MMP -3, MMP -13, MMP -14, MMP -25, TIMP-3, TIMP-4 and Caveolin-1 were differentially expressed during osteogenic differentiation, being upregulated only at 28 days post-induction and TIMP-1 upregulated from the first day of induction. MMP-11 and MMP-16 were not detected in DPSCs neither during differentiation. Thus, we conclude that MMPs, Caveolin-1 found as well as TIMP-3 and TIMP-4 may be participating in the event of bone differentiation in DPSCs, TIMP-1 may participate in biological events related to the properties of the undifferentiated state DPSCs and osteogenic differentiation, MMP-11 and MMP-16 are not also expressed by DPSCs and are not involved in osteogenic differentiation.

As células-tronco mesenquimais (MSCs) são células multipotentes que tem o potencial de se diferenciarem em várias linhagens celulares in vitro e in vivo. Estas são encontradas em nichos específicos em muitos órgãos e tecidos adultos, tais como medula óssea, tecido adiposo, músculo, dente, cordão umbilical, pele, cartilagem articular, sendo facilmente isoladas, expandidas e com alta capacidade proliferativa in vitro. Assim, estas características têm despertado grande interesse na sua utilização como uma potencial fonte de células para o reparo e regeneração tecidual de diversos órgãos e tecidos. Pouco se conhece sobre as moléculas que são secretadas pelas MSCs para a matriz extracelular (MEC) e que estão na interface célula-matriz e estão presentes em vias de transdução de sinais intracelulares. Desta forma, o objetivo deste trabalho foi avaliar o perfil de expressão gênica de enzimas que remodelam a MEC (metaloproteinases de matriz MMPs: 15 membros) e seus inibidores (inibidores teciduais das metaloproteinases de matriz TIMPs: 4 membros e RECK) e proteína da membrana plasmática (Caveolina-1) durante a diferenciação osteogenica in vitro a partir de células-tronco mesenquimais da polpa dentária humana (DPSCs). Para tanto, utilizamos polpas dentárias humanas provenientes de terceiros molares de indivíduos adultos (18-32 anos n=3) e as DPSCs isoladas foram imunofenotipadas por citometria de fluxo, avaliada a taxa de proliferação, induzidas as diferenciações osteogênica (1, 7, 14, 21 e 28 dias) e adipogênica (28 dias) e os transcritos avaliados por PCR em tempo real. Estas células foram positivas para o marcadores CD29, CD105, STRO-1, CD44, CD90 negativas os marcadores para CD31, CD45, CD34 e CD14 e são capazes de se diferenciarem em osteoblastos e adipócitos. Verificamos que as MMP-2, MMP-3, MMP-13, MMP-14, MMP-25, TIMP-3, TIMP-4 e Caveolina-1 foram diferencialmente expressas durante a diferenciação osteogênica, sendo reguladas positivamente apenas no período de 28 dias pós indução e a TIMP-1 regulada positivamente desde o primeiro dia de indução. A MMP-11 e MMP-16 não foram detectadas nas DPSCs e nem durante a diferenciação osteogênica. Desta forma, concluímos que MMPs encontradas bem como a Caveolina-1 e as TIMP-3 e TIMP-4 podem estar participando dos dos eventos de diferenciação óssea em DPSCs, a TIMP-1 pode estar participando de eventos biológicos relacionados as propriedades do estado indiferenciado das DPSCs e da diferenciação óssea e que as MMP-11 e MMP-16 não são expressas pelas DPSCs e também não estão envolvidas na diferenciação osteogênica. / Mesenchymal stem cells (MSCs) are multipotent cells that have the potential to differentiate into various cell lineages in vitro and in vivo. These are found in specific niches in many adult organs and tissues, such as bone marrow, adipose tissue, muscle, tooth, umbilical cord, skin, cartilage, being easily isolated, expanded and high proliferative capacity in vitro. Thereby, these features have attracted great interest in its use as a potential source of cells for tissue repair and regeneration of various organs and tissues. Little is known about the molecules secreted by MSCs into the extracellular matrix (ECM), present at cell-matrix interface and present on intracellular signal transduction. Thus, the aim of this study was to evaluate gene expression profile of ECM remodeling enzymes (matrix metalloproteinases MMPs: 15 members) and their inhibitors (tissue inhibitors of matrix metalloproteinases TIMPs: 4 members and RECK) and plasma membrane proteins (Caveolin-1) that participate in signaling pathways during osteogenic differentiation in vitro from human dental pulp stem cells (DPSCs). Normal human impacted third molars were collected from adults (18-32 years-old n=3) and DPSCs isolated were immunophenotyping by flow cytometry, evaluated the proliferation ratio, induced to osteogenic (1, 7, 14, 21 and 28-days) and adipogenic differentiation (28-days) and the transcript levels evaluated by Real Time PCR. These cells are positive for CD29, CD105, STRO -1, CD44, and CD90 markers and negative for CD31, CD45, CD34, and CD14 markers and are capable of differentiating into osteoblasts and adipocytes. We found that MMP- 2, MMP -3, MMP -13, MMP -14, MMP -25, TIMP-3, TIMP-4 and Caveolin-1 were differentially expressed during osteogenic differentiation, being upregulated only at 28 days post-induction and TIMP-1 upregulated from the first day of induction. MMP-11 and MMP-16 were not detected in DPSCs neither during differentiation. Thus, we conclude that MMPs, Caveolin-1 found as well as TIMP-3 and TIMP-4 may be participating in the event of bone differentiation in DPSCs, TIMP-1 may participate in biological events related to the properties of the undifferentiated state DPSCs and osteogenic differentiation, MMP-11 and MMP-16 are not also expressed by DPSCs and are not involved in osteogenic differentiation.

Die invasiven und metastatischen Eigenschaften vieler Tumore werden mit einer Veränderung im physiologischen Gleichgewicht der Matrix Metalloproteinasen (MMP) und ihrer spezifischen und unspezifischen Inhibitoren in Zusammenhang gebracht. Das Ziel dieser Dissertation war es, die Wirkung von Batimastat, einem synthetischen Inhibitor der MMP, auf hormonabhängige und hormonunabhängige Prostatakarzinomzellinien sowie auf das Tumorwachstum im orthotopen Tumormodell des Dunning Tumor (R3327) zu untersuchen. Methoden: Im Zellkulturversuch wurde die Wirkung verschiedener Konzentrationen von Batimastat untersucht und die Proliferation mit dem MTT Test gemessen. Die Induktion des orthotopen Tumors erfolgte durch Inokulation von MATLyLu Zellen in die Rattenprostata (Dunning Tumor der Copenhagen Ratte). 10 Tiere wurden nach Tumorinduktion täglich mit 30 mg/kg Batimastat durch intraperitoneale Gabe behandelt, 10 weitere Ratten erhielten nur das Vehikel. Zehn Kontrolltiere blieben unbehandelt. Der Effekt auf des lokale Tumorwachstum wurden durch Bestimmung des Tumorgewichtes nach 20 Tagen definiert. Results:Batimastat zeigte eine dosisabhänige Hemmung des Wachstums der Prostatakarzinomzellinien in vitro. Bei 4000 ng/ml kam es zu einer eindeutigen Hemmung des Zellwachstums. Im Tierversuch fand sich nach 20 Tagen in der Kontrollgruppe ein mittleres Tumorgewicht von 18.9 ± 5,4 g, in der Vehikelgruppe von 22.3 ± 4,3 g und in der mit Batimastat behandelten Gruppe von 11.1 ± 2,6 g. Im Vergleich zur Kontroll- und Vehikelgruppe, zeigte sich in der Batimastatgruppe ein signifikant geringeres Tumorgewicht. Zusammenfassung: Batimastat kann das Tumorwachstum in einem Standardtiermodell des Prostatakarzinoms vermindern. Der Dunning Tumor der Copenhagen Ratte ist ein zuverlässiges Tiermodell zur weiteren Untersuchung von synthetischen Inhibitoren der MMP. / Background: Increased concentrations of metalloproteinases are associated with the invasive and metastatic behavior of several human malignant tumors. Normally, enzymatic activity is tightly regulated by nonspecific mechanisms and specific inhibitors. The aim of this dissertation was to determine the potential of a synthetic metallproteinase inhibitor, batimastat, to show its in vitro effect on hormonedependent and hormoneindependent prostate cancer cell lines and its in vivo effect on tumor growth in orthotopic cancer (R3327 Dunning tumor) in rats. Methods: In vitro, a dose response curve of batimastat was generated over 5 days using the MTT assay. Prostate cancer was injected in vivo in male Copenhagen rats by inoculating R3327 Dunning tumor cells (MATLyLu) into the ventral prostatic lobe of 30 rats. Each of 10 rats received batimastat (30 mg / kg / body weight) or vehicle once a day by i.p. application beginning the day of cell inoculation. Ten rats remained untreated. The effect on local tumor growth was evaluated by measuring tumor weights 20 days after tumor cell inoculation. Results: Significant inhibiton of tumor cell proliferation in vitro occurred at 4000 ng / ml batimastat. After orthotopic cell inoculation, tumors grew to mean weights of 18.9 ± 5,4 g in the control group without treatment, to 22.3 ± 4,3 g in the vehicle group, an to 11.1 ± 2,6 g in the treated group. In comparison to the control group and to the vehicle group, tumor weights increased significantly less under treatment with batimastat. Conclusions: Batimastat is able to reduce tumor growth in the standard prostate cancer model. Using this model, activity against cancer progression of future inhibitory agents can be reliably assessed.